 |
Products |  |
Diseases | | Products |
|
Trials |  |
News |  |
- ||||| QRX003 / Cellect Biotechnology
Enrollment change: Open Label, Safety and Efficacy Study of QRX003 Lotion in Subjects With Netherton Syndrome (clinicaltrials.gov) - Apr 15, 2024
P2/3, N=20, Recruiting, Sponsor: Quoin Pharmaceuticals
N=10 --> 20
- ||||| QRX003 / Cellect Biotechnology
Enrollment change: Safety, Tolerability and Efficacy of QRX003 Lotion in Subjects With Netherton Syndrome (clinicaltrials.gov) - Apr 14, 2024
P2/3, N=30, Recruiting, Sponsor: Quoin Pharmaceuticals
N=10 --> 20 N=18 --> 30
- | QRX003 / Cellect Biotechnology
Trial completion date, Trial primary completion date: Safety, Tolerability and Efficacy of QRX003 Lotion in Subjects With Netherton Syndrome (clinicaltrials.gov) - Dec 31, 2023
P2/3, N=18, Recruiting, Sponsor: Quoin Pharmaceuticals
- QRX003 / Cellect Biotechnology
Trial completion date, Trial primary completion date: Open Label, Safety and Efficacy Study of QRX003 Lotion in Subjects With Netherton Syndrome (clinicaltrials.gov) - Nov 18, 2023
P2/3, N=10, Recruiting, Sponsor: Quoin Pharmaceuticals
N=18 --> 30 Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Jul 2023 --> Dec 2024
- | QRX003 / Cellect Biotechnology
New P2/3 trial: Open Label, Safety and Efficacy Study of QRX003 Lotion in Subjects With Netherton Syndrome (clinicaltrials.gov) - Mar 29, 2023
P2/3, N=10, Recruiting, Sponsor: Quoin Pharmaceuticals
- | QRX003 / Cellect Biotechnology
New P2/3 trial: Safety, Tolerability and Efficacy of QRX003 Lotion in Subjects With Netherton Syndrome (clinicaltrials.gov) - Aug 30, 2022
P2/3, N=18, Recruiting, Sponsor: Quoin Pharmaceuticals